Teva Pharmaceutical Industries Limited (NYSE:TEVA) was upgraded by equities research analysts at BTIG Research from a “neutral” rating to a “buy” rating in a research note issued to investors on Monday. The brokerage presently has a $24.00 price objective on the stock. BTIG Research’s price target would indicate a potential upside of 54.84% from the stock’s current price.

A number of other analysts have also recently commented on the stock. Mizuho upgraded shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and boosted their target price for the company from $25.00 to $30.00 in a report on Thursday, June 15th. Royal Bank Of Canada set a $38.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a report on Friday, June 16th. Vetr cut shares of Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $31.94 price target on the stock. in a research note on Monday, May 22nd. Credit Suisse Group reiterated a “buy” rating and issued a $39.00 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, May 17th. Finally, Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, May 31st. Five analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $33.32.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 15.50 on Monday. The company’s 50-day moving average is $21.00 and its 200 day moving average is $29.17. Teva Pharmaceutical Industries Limited has a 52 week low of $15.22 and a 52 week high of $52.66. The company’s market capitalization is $15.75 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. The company had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.25 earnings per share. On average, analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/11/teva-pharmaceutical-industries-limited-teva-lifted-to-buy-at-btig-research.html.

A number of institutional investors have recently added to or reduced their stakes in TEVA. San Francisco Sentry Investment Group CA purchased a new stake in Teva Pharmaceutical Industries Limited in the 2nd quarter worth approximately $106,000. Bronfman E.L. Rothschild L.P. increased its holdings in Teva Pharmaceutical Industries Limited by 7.8% in the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after acquiring an additional 261 shares in the last quarter. Kistler Tiffany Companies LLC increased its holdings in Teva Pharmaceutical Industries Limited by 74.7% in the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after acquiring an additional 1,571 shares in the last quarter. FNY Managed Accounts LLC purchased a new stake in Teva Pharmaceutical Industries Limited in the 1st quarter worth approximately $123,000. Finally, Sterling Investment Advisors Ltd. increased its holdings in Teva Pharmaceutical Industries Limited by 2.6% in the 1st quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after acquiring an additional 100 shares in the last quarter. 56.87% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.